Let's Get Started

Biotech

Here’s Who Just Picked Up Dynatronics Corp (NASDAQ:DYNT) Shares

Here’s Who Just Picked Up Dynatronics Corp (NASDAQ:DYNT) Shares

Apr 19, 2017

In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Dynatronics Corp (NASDAQ:DYNT) reported that Provco Ventures 1 Lp has picked up 8,110,472 of common stock as of 2017-04-19.

The acquisition brings the aggregate amount owned by Provco Ventures 1 Lp to a total of 8,110,472 representing a 24.0% stake in the company.

For those not familiar with the company, Dynatronics Corporation is a manufacturer and distributor of physical medicine products. The Company’s products include a line of medical equipment for physical medicine applications, including therapy devices, medical supplies and soft goods, treatment tables and rehabilitation equipment. Its products are used by physical therapists, chiropractors, sports medicine practitioners, podiatrists, physicians and other physical medicine professionals. Its physical medicine products include therapeutic modalities, such as Dynatron Solaris, including electrotherapy and thermal therapy, and 25 Series, including electrotherapy and ultrasound; manufactured capital products, including traction systems and wood furniture; manufactured supplies, including cold packs, straps, wedges, bolsters and mats; distributed capital products, including hydrotherapy, weight training equipment and pilates, and distributed supplies, including clinical accessories, sports med and taping products, lotions and gels.

A glance at Dynatronics Corp (NASDAQ:DYNT)’s key stats reveals a current market capitalization of 8.55 Million based on 3.04 Million shares outstanding and a price at last close of $2.85 per share.

Looking at insider activity, there are a few transactions worth noting.

Specifically, on 2011-03-29, Beardall picked up 1,400 at a purchase price of $0.97. This brings their total holding to 177,588 as of the date of the filing.

It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Dynatronics Corp (NASDAQ:DYNT) as things move forward to see if its progress aligns with these transactions.

Subscribe below and we’ll keep you on top of what’s happening before it moves markets.

 

 

 

read more
Flynn James E Picked Mannkind Corp (NASDAQ:MNKD) Shares

Flynn James E Picked Mannkind Corp (NASDAQ:MNKD) Shares

Apr 19, 2017

In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Mannkind Corp (NASDAQ:MNKD) reported that Flynn James E has picked up 5,217,391 of common stock as of 2017-04-19.

The acquisition brings the aggregate amount owned by Flynn James E to a total of 5,217,391 representing a 5.17% stake in the company.

For those not familiar with the company, MannKind Corporation is a biopharmaceutical company. The Company is focused on the discovery and development of therapeutic products for diseases, such as diabetes. Its product candidate is AFREZZA, which is an inhaled insulin used to control high blood sugar in adults with type I and type II diabetes and helps in glycemic control. AFREZZA consists of a dry formulation of human insulin delivered from a portable inhaler. AFREZZA utilizes its Technosphere formulation technology. Technosphere is a drug delivery platform that may allow the oral inhalation of a range of therapeutics. Technosphere powders are based on the Company’s fumaryl diketopiperazine (FDKP), which is a potential of Hydrogen (pH)-sensitive organic molecule that self-assembles into small particles under acidic conditions. The Company has also created a range of breath-powered, dry powder inhalers. Its inhalers can be produced in both a reusable (chronic treatment) and a single-use (acute treatment) format.

A glance at Mannkind Corp (NASDAQ:MNKD)’s key stats reveals a current market capitalization of 113.14 Million based on 95.78 Million shares outstanding and a price at last close of $1.22 per share.

Looking at insider activity, there are a few transactions worth noting.

Specifically, on 2017-01-03, Pfeffer picked up 4,540 at a purchase price of $0.54. This brings their total holding to 403,085 as of the date of the filing.

On the sell side, the most recent transaction saw Alinaya unload 6,294 shares at a sale price of $1.06. This brings their total holding to 131,413.

It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Mannkind Corp (NASDAQ:MNKD) as things move forward to see if its progress aligns with these transactions.

Subscribe below and we’ll keep you on top of what’s happening before it moves markets.

 

 

 

read more
Guess Who Picked Nexvet Biopharma Plc. (NASDAQ:NVET) Shares

Guess Who Picked Nexvet Biopharma Plc. (NASDAQ:NVET) Shares

Apr 19, 2017

In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Nexvet Biopharma Plc. (NASDAQ:NVET) reported that Farallon Capital has picked up 1,046,345 of common stock as of 2017-04-19.

The acquisition brings the aggregate amount owned by Farallon Capital to a total of 1,046,345 representing a 8.7% stake in the company.

For those not familiar with the company, Nexvet Biopharma public limited company is a clinical-stage biopharmaceutical company focused on transforming the therapeutic market for companion animals by developing and commercializing species-specific biologics. The Company’s platform technology, which it refers to as PETization, is an algorithmic approach that enables the Company to create monoclonal antibodies (mAbs) a type of biologic, that are designed to be recognized as self or native by an animal’s immune system, a property referred to as 100% species-specificity. PETization is designed to build upon the safety and efficacy data from clinically tested human therapies to create new therapies for companion animals. Biologics generally include mAbs, which are targeted antibodies derived from identical (clonal) cells. The Company’s advanced product candidates are in pivotal-phase development: ranevetmab (or NV-01) and frunevetmab (or NV-02).

A glance at Nexvet Biopharma Plc. (NASDAQ:NVET)’s key stats reveals a current market capitalization of 77.57 Million based on 11.75 Million shares outstanding and a price at last close of $6.61 per share.

Looking at insider activity, there are a few transactions worth noting.

Specifically, on 2016-03-04, Gearing picked up 9,000 at a purchase price of $3.35. This brings their total holding to 125,903 as of the date of the filing.

On the sell side, the most recent transaction saw Farrell unload 132 shares at a sale price of $3.27. This brings their total holding to 0.

It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Nexvet Biopharma Plc. (NASDAQ:NVET) as things move forward to see if its progress aligns with these transactions.

Subscribe below and we’ll keep you on top of what’s happening before it moves markets.

 

 

 

read more
Ocera Therapeutics Inc. (NASDAQ:OCRX) is Attracting Smart Money

Ocera Therapeutics Inc. (NASDAQ:OCRX) is Attracting Smart Money

Apr 17, 2017

In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Ocera Therapeutics Inc. (NASDAQ:OCRX) reported that Perceptive Advisors has picked up 2,150,000 of common stock as of 2017-04-17.

The acquisition brings the aggregate amount owned by Perceptive Advisors to a total of 2,150,000 representing approximately 9.11% stake in the company.

For those not familiar with the company, Ocera Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on acute and chronic orphan liver diseases. The Company is focused on the development and commercialization of its clinical candidate, OCR-002, for the treatment of hepatic encephalopathy (HE). OCR-002 is a molecule, ornithine phenylacetate, which functions as an ammonia scavenger. It is conducting a randomized, placebo-controlled double blind Phase IIb clinical trial to evaluate the efficacy of intravenous administration of OCR-002 IV formulation in reducing the severity of HE symptoms among HE patients. The Company also conducted a Phase IIa investigator-sponsored trial of OCR-002 in Spain in patients with upper gastrointestinal bleeding associated with liver cirrhosis. It is developing an oral form of OCR-002 to provide continuity of care for HE patients, where the intravenous form is used for hospital-based acute care and the oral form for chronic maintenance care post discharge.

A glance at Ocera Therapeutics Inc. (NASDAQ:OCRX)’s key stats reveals a current market capitalization of 37.96 Million based on 23.60 Million shares outstanding and a price at last close of $1.45 per share.

Looking at insider activity, there are a few transactions worth noting.

Specifically, on 2017-03-28, Byrnes picked up 3,000 at a purchase price of $1.28. This brings their total holding to 13,000 as of the date of the filing.

On the sell side, the most recent transaction saw Powell unload 11,969 shares at a sale price of $2.53. This brings their total holding to 0.

It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Ocera Therapeutics Inc. (NASDAQ:OCRX) as things move forward to see if its progress aligns with these transactions.

Subscribe below and we’ll keep you on top of what’s happening before it moves markets.

 

 

 

read more
Ronin Capital, Llc is Buying Peregrine Pharmaceuticals Inc. (NASDAQ:PPHM) Shares

Ronin Capital, Llc is Buying Peregrine Pharmaceuticals Inc. (NASDAQ:PPHM) Shares

Apr 17, 2017

In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Peregrine Pharmaceuticals Inc. (NASDAQ:PPHM) reported that Ronin Capital, Llc. has picked up 95,059 of common stock as of 2017-04-17.

The acquisition brings the aggregate amount owned by Ronin Capital, Llc. to a total of 95,059 representing approximately 5.8% stake in the company.

For those not familiar with the company, Peregrine Pharmaceuticals, Inc. (Peregrine) is a biopharmaceutical company. The Company operates through two segments: Peregrine, which is engaged in the research and development of monoclonal antibodies for the treatment of cancer, and Avid, which is engaged in providing contract manufacturing services for third party customers on a fee-for-service basis while also supporting its internal drug development efforts. Bavituximab is its lead immunotherapy candidate. Bavituximab is a monoclonal antibody that targets and binds to phosphatidylserine (PS), a immunosuppressive molecule that is usually located inside the membrane of healthy cells, but then flips and becomes exposed on the outside of cells in the tumor microenvironment, causing the tumor to evade immune detection. The Company’s subsidiary is Avid Bioservices, Inc. (Avid). Avid provides integrated current good manufacturing practices (cGMP) services from cell line development to commercial biomanufacturing.

A glance at Peregrine Pharmaceuticals Inc. (NASDAQ:PPHM)’s key stats reveals a current market capitalization of 158.77 Million based on 297.71 Million shares outstanding and a price at last close of 0.546 per share.

Looking at insider activity, there are a few transactions worth noting.

Specifically, on 2012-03-14, Swartz picked up 16,000 at a purchase price of $0.62. This brings their total holding to 126,000 as of the date of the filing.

It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Peregrine Pharmaceuticals Inc. (NASDAQ:PPHM) as things move forward to see if its progress aligns with these transactions.

Subscribe below and we’ll keep you on top of what’s happening before it moves markets.

 

 

 

read more

Schuler Jack W Picked Up Biolase Inc. (NASDAQ:BIOL) Shares

Apr 17, 2017

In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Biolase Inc. (NASDAQ:BIOL) reported that Schuler Jack W has picked up 20,728,060 of common stock as of 2017-04-17.

The acquisition brings the aggregate amount owned by Schuler Jack W to a total of 20,728,060 representing approximately 28.71% stake in the company.

For those not familiar with the company, BIOLASE, Inc. (BIOLASE) is a medical device company that develops, manufactures, markets and sells laser systems in dentistry and medicine. The Company markets, sells, and distributes dental imaging equipment, including cone beam digital x-rays and computer-aided design (CAD)/computer-aided manufacturing (CAM) intra-oral scanners, in-office, chair-side milling machines and three-dimensional (3-D) printers. It offers two categories of laser system products: WaterLase (all-tissue) systems and Diode (soft tissue) systems. Its brand, WaterLase, uses a combination of water and laser energy to perform procedures performed using drills, scalpels, and other traditional dental instruments for cutting soft and hard tissue. It also offers its Diode laser systems to perform soft tissue, pain therapy, and cosmetic procedures, including teeth whitening. Its Waterlase and Diode systems use disposable laser tips of differing sizes and shapes depending on the procedures being performed.

A glance at Biolase Inc. (NASDAQ:BIOL)’s key stats reveals a current market capitalization of 93.50 Million based on 67.66 Million shares outstanding and a price at last close of $1.32 per share.

Looking at insider activity, there are a few transactions worth noting.

Specifically, on 2015-10-21, Schuler picked up 33,762 at a purchase price of $0.95. This brings their total holding to 4,213,429 as of the date of the filing.

On the sell side, the most recent transaction saw Mulder unload 5,000 shares at a sale price of $1.25. This brings their total holding to 0.

It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Biolase Inc. (NASDAQ:BIOL) as things move forward to see if its progress aligns with these transactions.

Subscribe below and we’ll keep you on top of what’s happening before it moves markets.

 

 

 

read more
Here’s Who Just Picked Up Angiodynamics Inc. (NASDAQ:ANGO) Shares

Here’s Who Just Picked Up Angiodynamics Inc. (NASDAQ:ANGO) Shares

Apr 14, 2017

In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Angiodynamics Inc. (NASDAQ:ANGO) reported that Avista Capital Partners Gp, Llc. has picked up 2,333,008 of common stock as of 2017-04-14.

The acquisition brings the aggregate amount owned by Avista Capital Partners Gp, Llc. to a total of 2,333,008 representing a 6.3% stake in the company.

For those not familiar with the company, AngioDynamics, Inc. designs, manufactures and sells a range of medical, surgical and diagnostic devices used by professional healthcare providers for vascular access, for the treatment of peripheral vascular disease and for use in oncology and surgical settings. The Company’s devices are used in minimally invasive, image-guided procedures. The Company offers products within three product groupings: Peripheral Vascular, Vascular Access and Oncology/Surgery. The Company’s Peripheral Vascular products include Fluid Management, Venous, Thrombus Management, as well as other core products. The Company’s BioFlo products incorporate Endexo Technology into the manufacturing and design of its Vascular Access products. Its Oncology/Surgery product offerings include its Microwave Ablation products, Radiofrequency Ablation (RFA) and its NanoKnife product lines.

A glance at Angiodynamics Inc. (NASDAQ:ANGO)’s key stats reveals a current market capitalization of 558.82 Million based on 36.79 Million shares outstanding and a price at last close of $15.19 per share.

Looking at insider activity, there are a few transactions worth noting.

Specifically, on 2014-04-14, Kapusta picked up 1,000 at a purchase price of $13.90. This brings their total holding to 27,005 as of the date of the filing.

On the sell side, the most recent transaction saw Burgstahler unload 384,184 shares at a sale price of $16.00. This brings their total holding to 381,406.

It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Angiodynamics Inc. (NASDAQ:ANGO) as things move forward to see if its progress aligns with these transactions.

Subscribe below and we’ll keep you on top of what’s happening before it moves markets.

 

 

 

read more
Here’s Who Just Picked Up Neos Therapeutics Inc. (NASDAQ:NEOS) Shares

Here’s Who Just Picked Up Neos Therapeutics Inc. (NASDAQ:NEOS) Shares

Apr 14, 2017

In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Neos Therapeutics Inc. (NASDAQ:NEOS) reported that Dammeyer Rodney F has picked up 1,001,568 of common stock as of 2017-04-14.

The acquisition brings the aggregate amount owned by Dammeyer Rodney F to a total of 1,001,568 representing a 6.2% stake in the company.

For those not familiar with the company, Neos Therapeutics, Inc. is a pharmaceutical company. The Company is focused on developing, manufacturing and commercializing products utilizing its modified-release drug delivery technology platform. Its segment is engaged in the development, manufacturing and commercialization of pharmaceuticals. It has utilized its platform to develop its product for the treatment of attention deficit hyperactivity disorder (ADHD). Its product candidates are extended-release (XR), medications in patient-friendly, orally disintegrating tablets (ODT) or liquid suspension dosage forms. Its branded product and product candidates incorporate over two of the prescribed medications for the treatment of ADHD, methylphenidate and amphetamine. Its modified-release drug delivery platform has enabled it to create extended-release ODT and liquid suspension dosage forms of the medications. It focuses on developing Adzenys XR-ODT, Cotempla XR-ODT and NT-0201.

A glance at Neos Therapeutics Inc. (NASDAQ:NEOS)’s key stats reveals a current market capitalization of 152.29 Million based on 22.56 Million shares outstanding and a price at last close of $6.80 per share.

Looking at insider activity, there are a few transactions worth noting.

Specifically, on 2016-08-31, Fong picked up 1,500 at a purchase price of $6.54. This brings their total holding to 1,500 as of the date of the filing.

On the sell side, the most recent transaction saw Presidio unload 213 shares at a sale price of $9.88. This brings their total holding to 39,998.

It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Neos Therapeutics Inc. (NASDAQ:NEOS) as things move forward to see if its progress aligns with these transactions.

Subscribe below and we’ll keep you on top of what’s happening before it moves markets.

 

 

 

read more
Uluru Inc. (OTCMKTS:ULUR) is Attracting Smart Money

Uluru Inc. (OTCMKTS:ULUR) is Attracting Smart Money

Apr 13, 2017

In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Uluru Inc. (OTCMKTS:ULUR) reported that Sacks Michael Ivan has picked up 43,711,970 of common stock as of 2017-04-13.

The acquisition brings the aggregate amount owned by Sacks Michael Ivan to a total of 43,711,970 representing a 48.4% stake in the company.

For those not familiar with the company, ULURU Inc. is a specialty pharmaceutical company focused on developing and commercializing a range of wound care and muco-adhesive film products based on its Nanoflex and OraDisc technologies for patients, healthcare professionals and healthcare payers. The Company operates through the research, development and commercialization of pharmaceutical products segment. Utilizing its technologies, three of its products have been approved for marketing in various global markets. Altrazeal Transforming Powder Dressing is based on its Nanoflex technology, which changes the way healthcare providers approach their treatment of wounds. The product is indicated for both exuding acute wounds, such as donor sites, non-healing surgical wounds, and trauma and for chronic wounds, such as venous leg ulcers, diabetic foot ulcers and pressure ulcers. Aphthasol is a drug approved for the treatment of canker sores. OraDisc is developed as an improved drug delivery system for the treatment of canker sores.

A glance at Uluru Inc. (OTCMKTS:ULUR)’s key stats reveals a current market capitalization of 4.26 Million based on 62.97 Million shares outstanding and a price at last close of $0.0677 per share.

Looking at insider activity, there are a few transactions worth noting.

Specifically, on 2016-03-29, Wallberg picked up 701,262 at a purchase price of $0.07. This brings their total holding to 825,519 as of the date of the filing.

On the sell side, the most recent transaction saw Oss unload 3,400,000 shares at a sale price of $0.16. This brings their total holding to 8,061,522.

It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Uluru Inc. (OTCMKTS:ULUR) as things move forward to see if its progress aligns with these transactions.

Subscribe below and we’ll keep you on top of what’s happening before it moves markets.

 

 

 

read more